Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Ovarian Neoplasms 69Neoplasms 21Breast Neoplasms 21Fallopian Tube Neoplasms 18Prostatic Neoplasms 15Neoplasm Metastasis 9Pancreatic Neoplasms 8Endometrial Neoplasms 8Carcinoma, Ovarian Epithelial 8Glioblastoma 7Triple Negative Breast Neoplasms 6Lung Neoplasms 5Small Cell Lung Carcinoma 4Glioma 4Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Mesothelioma 3Melanoma 3Head and Neck Neoplasms 3Cystadenocarcinoma, Serous 3Cholangiocarcinoma 3Carcinoma 3Uterine Neoplasms 2Uterine Cervical Neoplasms 2Urogenital Neoplasms 2Stomach Neoplasms 2Solid Tumor 2Sarcoma 2Prostatic Neoplasms, Castration-Resistant 2Ovarian Diseases 2

Interventions

enzalutamide 20Abiraterone Acetate 11Prednisone 7Docetaxel 7radium Ra 223 dichloride 6darolutamide 5abiraterone 5apalutamide 3olaparib 2niraparib 2cabazitaxel 2atezolizumab 2Pluvicto 2Nivolumab 2zimberelimab 1xentuzumab 1tasquinimod 1sacituzumab govitecan 1sabizabulin 1quemliclustat 1pembrolizumab 1ipatasertib 1ibrutinib 1gedatolisib 1gallium 68 PSMA-11 1fludrocortisone acetate 1TVB-2640 1Standard of Care 1Rosuvastatin Calcium 1Radium-223 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Prostatic Neoplasms, Castration-Resistant × niraparib × Clear all
NCT03431350 2026-05-11

QUEST

Janssen Research & Development, LLC

Phase 2 Active not recruiting
136 enrolled 29 charts
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT03748641 2026-05-08

MAGNITUDE

Janssen Research & Development, LLC

Phase 3 Active not recruiting
765 enrolled 16 charts 1 FDA
Genitourinary

Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡